Trying times in HIV research
Since he began working on the development of a vaccine against HIV in 1984, Phillip Berman, Ph.D., has encountered many obstacles, both scientific and otherwise. There are the technical difficulties of actually engineering a vaccine, of course. But there are also the problems posed by working in a field that garners so much public attention. For the background on Berman's research, read a profile of him in the Fall 2011 issue of Dartmouth Medicine. And below, find a timeline of important events in the history of HIV vaccine research, including links to relevant articles in scientific journals and the popular press.
Doctors in New York and California begin to see a number of cases of what will come to be known as AIDS (Acquired Immune Deficiency Syndrome)
Luc Montagnier, M.D., a French scientist, and Robert Gallo, M.D., an American scientist, identify HIV (human immunodeficiency virus) as the cause of AIDS.
A vaccine developed by Berman and colleagues at Genentech proves to be effective in chimpanzees.
As the NIH considers whether to fund a phase III trial of the Genentech vaccine, an article in the Chicago Tribune raises fears about the safety of the vaccine.
After the NIH's decision not to fund a phase III trial, an extensive New York Times article investigates the history of the gp120 vaccine and its future.
Berman and Donald Francis, M.D., Ph.D., publish their plans for a phase III trial of the gp120 vaccine.
With the phase III trials of the gp120 vaccine underway, science writer Patricia Thomas publishes a comprehensive look at attempts by Berman, Francis, and other groups to develop an HIV vaccine and discusses some of the many obstacles they faced in their efforts. Wired magazine also covers the phase III trial, recapping the problems Berman and Francis faced along the way.
- Thomas's book, Big Shot
- an interview with Patricia Thomas
- Wired article: Testing the First AIDS Vaccine
At a conference in Canada, Berman announces the disappointing results of the trial.
- Berman, Francis, and their colleagues publish the results of the phase III trial and discuss what was learned.
- Science article on the results of the trial.
Despite the failure of the gp120 vaccine, another research group decides to combine it with a second vaccine and test the combination in a large trial in Thailand. Surprisingly, the combination proves to be 30% effective—the first such success of any HIV vaccine.
If you'd like to offer feedback about this article, we'd welcome getting your comments at DartMed@Dartmouth.edu.
This article may not be reproduced or reposted without permission. To inquire about permission, contact DartMed@Dartmouth.edu.